Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,376 GBX | -1.78% | -0.23% | +16.75% |
Jun. 10 | European Equities Close Lower in Monday Trading Following Far Right Gains in EU Elections | MT |
Jun. 10 | UK Stocks Join Europe Retreat Ahead of US Fed Rate Decision | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.75% | 249B | B+ | ||
+48.53% | 779B | C+ | ||
+40.67% | 631B | B | ||
-6.37% | 354B | C+ | ||
+20.93% | 333B | B- | ||
+8.21% | 301B | C+ | ||
-1.19% | 216B | A+ | ||
+10.85% | 214B | B- | ||
+4.40% | 163B | C+ | ||
-2.64% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC